RxDoctor Payments Data

Jannelle Vicens, APRN

Nurse Practitioner · Miami, FLNPI 1184016453

Payments from drug & device makers

$1,922in general payments, 2019–2025

Across 34 payments — averaging $56.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$843
  • Johnson & Johnson$224
  • Pfizer$223
  • Bristol Myers Squibb$158
  • Astellas Pharma US Inc$88
  • Adaptive Biotechnologies Corporation$88
  • plus $299 from 9 others

What the payments were for

  • Consulting fees$84344%
  • Food & beverage$93148%
  • Education$1488%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,922 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$6,124
Medicare patients
39
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide125$2,011,714
PomalystPomalidomide31$691,075
Lenalidomide26$341,255
CalquenceAcalabrutinib Maleate18$272,170
VonjoPacritinib Citrate13$224,978
Acyclovir82$850
Fluconazole19$721
Entecavir12$443
Ursodiol11$391
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim66$362
Folic Acid31$242
Levofloxacin14$223
Famotidine11$139
Gabapentin12$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$158$2,011,714125 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$843$691,07531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →